Generic placeholder image

Infectious Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5265
ISSN (Online): 2212-3989

Case Report

An Experience with Delamanid in an XDR TB Case – Case Report

Author(s): Nimitha Mohan, Manharpreet Kaur, Lipika Singhal*, Varinder Saini and Jagdish Chander

Volume 21, Issue 4, 2021

Published on: 20 July, 2020

Page: [637 - 639] Pages: 3

DOI: 10.2174/1871526520666200720113711

Price: $65

Abstract

Introduction: Tuberculosis is an endemic infection and a serious public health problem in India. India constitutes one-fourth of the global TB population. The emerging drug resistance is a major threat to global tuberculosis care and control.

Case report: We present a case of newly diagnosed microbiologically confirmed, extremely drugresistant primary pulmonary tuberculosis which was treated with Delamanid and was found to be cured of tuberculosis.

Discussion: Delamanid is a new anti-tubercular drug, which is thought to primarily inhibit the synthesis of methoxy-mycolic, and keto-mycolic acid, which are components of the mycobacterial cell wall. In our patient who was a newly diagnosed case of MDR-TB converted to XDR-TB in little course of time and we were successful in treating him with Delamanid therapy. His sputum culture conversion was achieved in 20 days. Even though the patient did not tolerate well because of the side effects of the drug, still he became microbiologically negative for tuberculosis.

Conclusion: Delamanid fulfills many target criteria for new TB drugs and may be particularly useful for the treatment of MDR-TB. It can be administered orally and its bactericidal properties make it suitable in regimens designed to shorten treatment duration. Clinical efficacy data, while limited, are reassuring.

Keywords: XDR-TB, drug defaulter, delamanid, cure of TB, methoxy-mycolic, MDR-TB.

[1]
Global TB Report; World Health Organization: Geneva, 2018.
[2]
Central, T.B. Division. Guidelines on Programmatic Management of Drug Resistant TB in India 2017. Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India; Central TB Division: New Delhi, 2017. Available from: https://tbcindia.gov.in/index1.php?lang=1&level=1&sublinkid=4782&lid=3306
[3]
World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis, 2016. Available from: http://apps.who.int/iris/bitstream/10665/250125/1/9789241549639-eng.pdf?ua=1
[4]
World Health Organization. The End TB Strategy, 2016. Available from: http://www.who.int/tb/strategy/End_TB_Strategy.pdf?ua=1
[5]
Saleri, N.; Badoum, G.; Ouedraogo, M.; Dembele, S.M.; Nacanabo, R.; Bonkoungou, V.; Cirillo, D.; Pinsi, G.; Matteelli, A. Extensively drug-resistant tuberculosis, Burkina Faso. Emerg. Infect. Dis., 2010, 16(5), 840-842.
[http://dx.doi.org/10.3201/eid1605.091262] [PMID: 20409379]
[6]
Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for Multidrug-Resistant Pulmonary Tuberculosis. June 7, 2012. N. Engl. J. Med., 2012, 366, 2151-2160.
[7]
Bakayoko, A.S.; Ahui, B.J.; Kone, Z.; Daix, A.T.; Samake, K.; Domoua, K.M.; Aka-Danguy, E. Extensively drug resistant tuberculosis in Ivory Coast. Rev. Pneumol. Clin., 2015, 71(6), 350-353.
[http://dx.doi.org/10.1016/j.pneumo.2014.12.009] [PMID: 25727655]
[8]
Sarin, R.; Vohra, V.; Singla, N.; Singla, R.; Puri, M.M.; Munjal, S.K.; Khalid, U.K.; Myneedu, V.P.; Verma, A.; Mathuria, K.K. Early efficacy and safety of Bedaquiline and Delamanid given together in a “Salvage Regimen” for treatment of drug-resistant tuberculosis. Indian J. Tuberc., 2019, 66(1), 184-188.
[http://dx.doi.org/10.1016/j.ijtb.2019.02.006] [PMID: 30878066]
[9]
VijaSkripconoka Manfred Danilovits Lea Pehme Tarmo Tomson Girts Skenders etal. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis European Respiratory Journal, 2013, 41, 1393-1400.
[10]
Otsuka Gmb, H. Otsuka Announces Worldwide Access Plan for Delamanid with Stop TB Partnership’s Global Drug Facility., 2016. Available from: www.prnewswire.com/news-releases/otsuka-announcesworldwide-access-plan-for-delamanid-with-stop-tb-partnerships-global- drug-facility- 569953021.html
[11]
World Health Organization. Global Tuberculosis Report 2017, 2017. Available from: http://apps.who.int/iris/bitstream/10665/259366/1/9789241565516- eng.pdf

Rights & Permissions Print Export Cite as
© 2023 Bentham Science Publishers | Privacy Policy